Stanley-Laman Group
MDGL icon

Stanley-Laman Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Stanley-Laman Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.54M Buy
+12,984
New +$6.86M 0.72% 36
2019
Q4 		– Sell
-2,447
Closed -$211K – 284
2019
Q3 		$211K Hold
2,447
– – 0.05% 256
2019
Q2 		$256K Buy
+2,447
New +$262K 0.06% 246

Other funds holding MDGL

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bourgeon Capital Management
Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return
Shikiar Asset Management
Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return
Quadrant Capital Group
Quadrant Capital Group Cincinnati, Ohio $3.7B AUM 33.76% 1-Year Est. Return

Stanley-Laman Group's MDGL Position: Q3 2026 in Review

Stanley-Laman Group opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 12,984 shares worth $6.54M. The stake represents 0.72% of the portfolio and ranks #36 among its holdings. This is a return to the name: Stanley-Laman Group previously reported a position in MDGL as recently as Q3 2019.

Stanley-Laman Group first reported a position in MDGL in Q2 2019 and has held it in 3 quarters since. 58 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Stanley-Laman Group held 12,984 shares of Madrigal Pharmaceuticals worth $6.54M as of Q3 2026.
  • Madrigal Pharmaceuticals was a new Stanley-Laman Group position in Q3 2026.
  • Madrigal Pharmaceuticals made up 0.72% of Stanley-Laman Group's portfolio in Q3 2026, its #36 holding.
  • Stanley-Laman Group first reported a position in Madrigal Pharmaceuticals in Q2 2019 and has held it in 3 quarters since.
  • 58 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Stanley-Laman Group's 13F filing for Q3 2026, filed 20 Oct 2026.